⌘K

Login Start Free

Home/Filings/4/0001062993-22-001695

4//SEC Filing

Dorling Janet 4

Accession 0001062993-22-001695

CIK 0001042074other

View on SEC.gov Company Profile

Filed

Jan 26, 7:00 PM ET

Accepted

Jan 27, 4:54 PM ET

Size

5.3 KB

Accession

0001062993-22-001695

Insider Transaction Report

Form 4

Period: 2022-01-25

CymaBay Therapeutics, Inc.CBAY

Chief Commercial Officer

Transactions

Award
Stock Option (right to buy)
2022-01-25+67,000→ 67,000 total
Exercise: $2.94Exp: 2032-01-24→ Common Stock (67,000 underlying)

Footnotes (1)

[F1]The option vests as to 1/12 of the underlying shares monthly from January 1, 2022.

Documents

1 file

4
form4.xmlPrimary
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Issuer

CymaBay Therapeutics, Inc.

CIK 0001042074

Entity typeother

Related Parties

1

filerCIK 0001738144

Filing Metadata

Form type: 4
Filed: Jan 26, 7:00 PM ET
Accepted: Jan 27, 4:54 PM ET
Size: 5.3 KB

View on SEC.gov